A CLEAR Upfront Winner in Advanced RCC?

(MedPage Today) -- Pembrolizumab (Keytruda) plus lenvatinib (Lenvima) improved survival outcomes and response rates as a first-line treatment for advanced renal cell carcinoma (RCC), the randomized phase III CLEAR study showed.
For the primary...